Immunotoxin-Based Targeted Therapy for Cancer, CCR4 Bispecific

Fri, 10 Apr 2026 01:20:46 +0000
Intellectual Property

The USPTO published patent application US20260098097A1 for methods of treating cancer using a genetically engineered C-C motif chemokine receptor 4 (CCR4) bispecific immunotoxin. The application, filed December 29, 2023, covers treatment of cutaneous T-cell lymphoma and other cancers via administration of the immunotoxin alone or in combination with additional therapeutic agents such as antibody-drug conjugates.